Table 1. Effects of PFD on cardiac hypertrophy in rats with cardiac fibrosis.

Group	Dose (mg/kg)	BW (g)	HW (mg)	LVW (mg)	HW/BW (mg/g)	LVW/BW (mg/g)
Sham	—	467 ± 32.6	1231 ± 56.3	849.9 ± 40.3	2.6 ± 0.1	1.8 ± 0.1
Model	—	454.8 ± 23.8	1351 ± 77.6**	916.5 ± 47.4**	2.9 ± 0.1**	2.0 ± 0.1**
PFD	300	423.7 ± 20.3##	1228 ± 66.5##	844.8 ± 50.6##	2.7 ± 0.1	1.9 ± 0.1
Losartan	20	430 ± 28.8#	1237 ± 100.7##	853.9 ± 53.1##	2.8 ± 0.1	1.9 ± 0.1

Data are reported as means ± SEM (n = 13 for sham group, 12 for model group, 13 for PFD group, and 13 for losartan group). Differences between groups were examined by ANOVA followed by Dunnett’s test. PFD, Pirfenidone; BW, the body weight; HW, heart weight; LVH, left ventricular weight. **P < 0.01 vs. sham group. ^#P < 0.05, ^##P < 0.01 vs. model group.